Keywords
Hepatitis B, mathematical model, positivity and existence, global stability, sensitivity, Lyapunov method, simulation
This article is included in the Pathogens gateway.
This article is included in the Bioinformatics gateway.
Hepatitis B, mathematical model, positivity and existence, global stability, sensitivity, Lyapunov method, simulation
Dear Editor,
These are the corrections made in the article as listed by the reviewer:
1. Under Abstract - I changed positivity solution to positivity of solutions
2. Under Introduction - line 3 - I changed reporting to reported.
3. The aim of this study is to contribute to the development of HBV control strategies and the establishment of intermediate objectives for intervention programs in Paragraph 4 is written as “The aim of this study is to forestall the development of HBV control strategies and the establishment of intermediate objectives for intervention programs”.
4. Lemma 1 is rewritten as: Suppose the initial values are.
5. The solution of the model (3) is positively invariant for all t>0 not t≥0
Hence, under the proof S>0 not S≥0, A>0 not A≥0
See the authors' detailed response to the review by Abimbola Abolarinwa
Hepatitis B is a common liver infection caused by the potentially life-threatening hepatitis B virus (HBV). HBV can cause a serious infection, which places individuals at high risk of dying from fibrosis and cirrhosis of liver. It is a huge worldwide health issue. As reported by the World Health Organization, around 360 million of the 2 billion people infected with the HBV are reported to have a lifelong chronic infection, and 887,000 of those individuals die from liver cirrhosis or primary hepatocellular carcinoma (WHO, 2020). As of 2016, 27 million individuals (10.5%) of all people considered to be living with HBV were aware of their infection, while 4.5 million (16.7%) of those diagnosed were receiving treatment (WHO, 2019). The Western Pacific region recorded the highest incidence rate of HBV at 6.2% of the adult population, while this was 6.1% in the African region, and 0.7% in the American region on (WHO, 2019). Although HBV lives outside the body for about seven days, it is still very possible for it to cause an infection if it is injected into an unvaccinated individual. It takes about 75 days on the average for the HBV to incubate but this can vary between 30 and 180 days. Detection of the virus can be between 30 and 60 days of being infected or consequently mature into full-blown HBV (CDC, 2019).
The HBV, a hepatotropic non-cytopathic virus, is responsible for the disease (Ribiero, 2002). In highly endemic areas, perinatal transmission or horizontal transmission (exposure to infected blood) are the primary means of transmission (Pan and Zhang, 2005). The most common method of transmission is from mother to child at birth, particularly from infected children to uninfected children within the first 5 years of life. Contaminated body fluids such as vaginal discharge, saliva, menstrual flow, and semen are other means of transmission (Pan and Zhang, 2005). Rarer means of transmission include transpiration, breast milk, sweat, and urine by percutaneous or mucosal exposure of infected individuals (Mpeshe and Nyerere, 2019). In particular, unvaccinated men who have sex with men and heterosexual people with several sexual partners or who have contact with sex workers may experience sexual transmission of HBV (Khan et al., 2019). In less than 5% of cases, infections lead to chronic hepatitis in adulthood. Virus transmission can also occur either in health care facilities or through the reuse of needles and syringes among individuals who inject drugs. Furthermore, infection can occur during medical, surgical and dental procedures, by tattooing, or by using razors and similar products contaminated with infected blood (Mpeshe and Nyerere, 2019).
Typically, there is a 5-10% chance of recovery for adults that develop chronic infections (Chenar et al., 2018). Host variables are believed to be responsible for determining whether the infection is cleared or becomes chronic, especially immune responses (Ciupe et al., 2007). Different aspects of HBV dynamics and the immune response during infection have been investigated by several mathematical models (Ribiero, 2002; Long et al., 2008; Lau et al., 2009; Wang et al., 2010; Qesmi et al., 2010; Pang et al., 2010).
As a result of the research mentioned above, we present an infectious disease model to better understand how testing and treatment at all infectious state affects HBV transmission dynamics and prevalence. The model formulation of HBV transmission dynamics, as well as the dynamical behavior of the model, including equilibria and stabilities is presented in this paper. The aim of this study is to forestall the development of HBV control strategies and the establishment of intermediate objectives for intervention programs.
It has been clinically shown that a proportion of HBV acutely infected individuals can spontaneously clear the virus (Pan and Zhang, 2005). Also, infectious individuals under treatment can become prone to re-infection if they discontinue treatment, or consume alcohol or use of drugs, which can reduce the impact of the treatment. In view of this, the following model is developed where the population is divided into different states, namely: the susceptible, the acute, the chronic carriers, the treated and the recovered states.
At time, denoted by the total population is divided into the following five classes/subgroups (Table 1) corresponding to different epidemiological status.
where are the susceptible populace, is the populace that are acutely infected with HBV, are the chronically/clinically infected individuals, while are individuals under treatment and are the recovered classes.
Figure 1 schematically represents the epidemiology of HBV. The various disease stages are replicated by the various compartments (circle) and the arrows demonstrate the way an individual progress from one state to the other. It is assumed that at time susceptible individual enter the population at a constant rate where is the birth rate, is the proportion of population successfully immunized, while is the probability that children born to carrier mothers will develop to chronic state. For all classes, individuals die at a constant natural mortality rate, We assume that HBV infected individuals on treatment are infectious. Susceptible individual may acquire HBV infection when in contact with individuals in populace at a rate (force of infection associated with HBV), where
where and are the effective contact rate for HBV infection to occur/probability that a contact will result in an Acute and Chronic HBV compartment, respectively. Modification accounts for a higher risk of HBV acquisition for people living with Chronic HBV.
A proportion of the acute HBV infected individuals becomes chronic carriers and then get treated at while the remaining proportion spontaneously clear the virus. is the duration of acute phase. A proportion of the treated HBV individuals, recover with full immunity, some were in the process of recovering in the treated populace at a rate, and duration for the treatment is given as while the remaining proportion becomes susceptible. Those individuals in the process of recovering in the treated populace at a rate, if engaging/exposed to high-risk habit and those on treatment can be re-infected at the rate if they discontinue treatment at a rate of .
where
From model (3), we observed that the variables are nonnegative and the solutions are non-negative for all time The parameters used are assumed to be positive and show that the feasible solutions are bounded in the region.
Lemma 1: Suppose the initial values are:
Then the solution of the model is positive for all
Proof: Considering the first equation in (3),
Hence,
With respect to the second equation in (3), we have
Hence,
The same approach applies to the proof of the positivity of C, T and R.
The disease-free equilibrium of the model (3) exists and is given by:
The endemic steady state of the model (3) exists and is presented as follows:
where
By using the next generation matrix, the basic reproduction number is determined and given by:
The reproduction number is given by ρ(FV−1), and
The global stability of the disease-free equilibrium was investigated using the Comparison method at the disease - free equilibrium . Theorem 1 proves the global stability of disease -free equilibrium
Theorem 1: The disease - free equilibrium of system (3) is globally asymptotically stable if and unstable if .
Proof: The Comparison method as implemented in Lashmkantham, et al (1989) and Mushayabasa et al (2011) is used here. The rate of change of the acute and chronic components of system (3) can be written as
Since at the disease free and as .
Then all eigenvalues of the matrix have negative real parts, i.e
Equation (11) has three negative roots by Descartes rule of signs if
It follows that the linearized differential inequality is stable whenever . Consequently, as . Evaluating system (3) at gives for . Hence, the disease-free equilibrium of system (3) is globally asymptotically stable if . The result also follows immediately that the disease-free equilibrium of system (3) is unstable if .
Theorem 2: The equations of the model has a positive distinctive endemic equilibrium whenever R0 > 1, which is said to be globally asymptotically stable.
Proof: Considering the Lyapunov function defined as:
where L takes it derivative along the system directly as:
At equilibrium,
where,
and whenever
Thus,
if the condition in (19) and (20) holds.
Therefore, by LaSalle asymptotic stability theorem (LaSalle, 1976), and Adeniyi et al. (2020), the positive equilibrium state is globally asymptotically stable in the positive region.
To test the strength of the model and the parameter values, a sensitivity study was carried out. This is done in order know the parameters that have a huge influence on the basic reproduction number (R0) which is done using Maple 19 software. A variable k; a normalized forward sensitivity index which depends on a parameter: differentially, is defined as:
The R0 sensitivity is therefore derived from each of the different parameters listed in Table 1. All expressions are complex for sensitivity indices, so sensitivity indices are evaluated in Table 2 at the baseline parameter values.
To validate our analytical results, we perform numerical simulations of the proposed model (2). These simulations are based on qualitative analysis. Some of the parameters were obtained from published research, while others were estimated by the authors as they were thought to be biologically feasible. We employ a strictly numerical RK (Runge-Kutta) technique of order four embedded in the Maple 19 software. Table 3 contains the parameter's comprehensive values.
Considering the first sizes of compartmental population, taking the parameter values and the interval (0-60) using the linear stability analysis, we perform the simulations and obtain the outcomes shown in Figure 2. The dynamic behavior of susceptible individuals is represented in Figure 2A, showing the existence of the susceptible individuals. It was discovered from Figure 2B that the acute populace decreases with the passage of time. Ditto the behaviors of chronic, treated and recovered populace, respectively, are dynamically represented in Figure 2C, D and E. The trajectories S(t), A(t), C(t), T(t), and R(t) distinctly converge to the disease-free equilibrium of E0 = (S_0, 0, 0, 0, 0, R_0) = (1.678018396, 0, 0, 0, 0, 0, 0, 0.06801334973) as indicated in Eq. (10), when R0 = 0.07150316516< 1. The dynamics of the susceptible populace with respect to the treatment rate σ, recovering rate with full immunity k and the rate at which recovered individual fallout from risk reduction ϵ is shown in Figure 3A. It is evident from Figure 3A that with the increase in the parametric values, the susceptible population increases, even as increase is not evident due to those who recover with complete immunity. However, there is still an increase due to some people who fall out of risk reduction, checking the cumulative impact of the parameters causing the increment of the susceptible populations. The inverse relationship of the compartmental population (acute and chronic) with the variance of the above parameters is shown in Figure 3B and C. This means that it is possible to minimize acute and chronic individuals by increasing the parametric values. The variation of the treated and recovered populace is shown in Figure 3D and E. An increase in the treated and the recovered population is caused by increasing the values of the parameters. It can be clearly inferred from our computational simulations that treatment, spontaneous clearance and reduction of the risk factor are highly successful in transmitting and regulating HBV transmission. The effective measure of these parameters as substantiated by the simulations is an excellent control method of the transmissible infection of HBV.
A deterministic model of hepatitis B that involves the spontaneous clearance of an acute individual and also recovery of chronic individual with full immunity and risk factor reduction was developed and investigated. Disease-free and endemic equilibria of the model exist. The basic reproduction number was constructed by the method of next generation matrix. The global stability of the disease-free and endemic equilibria was discussed and shown to be asymptotically stable. The effects of the treatment rate, the recovery rate with complete immunity, and the risk mitigation factor were thoroughly discussed. Future work may include using the optimum control theory to mitigate hepatitis B infection.
All data underlying the results are available as part of the article and no additional source data are required.
Views | Downloads | |
---|---|---|
F1000Research | - | - |
PubMed Central
Data from PMC are received and updated monthly.
|
- | - |
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Partly
If applicable, is the statistical analysis and its interpretation appropriate?
Yes
Are all the source data underlying the results available to ensure full reproducibility?
Yes
Are the conclusions drawn adequately supported by the results?
Yes
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Modeling Mathematics
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Partly
If applicable, is the statistical analysis and its interpretation appropriate?
Not applicable
Are all the source data underlying the results available to ensure full reproducibility?
Yes
Are the conclusions drawn adequately supported by the results?
Yes
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Mathematical Biology
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
Not applicable
Are all the source data underlying the results available to ensure full reproducibility?
Partly
Are the conclusions drawn adequately supported by the results?
Yes
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Differential equations, Differential Geometry
Alongside their report, reviewers assign a status to the article:
Invited Reviewers | |||
---|---|---|---|
1 | 2 | 3 | |
Version 2 (revision) 21 Jan 22 |
read | read | |
Version 1 28 May 21 |
read |
Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list:
Sign up for content alerts and receive a weekly or monthly email with all newly published articles
Already registered? Sign in
The email address should be the one you originally registered with F1000.
You registered with F1000 via Google, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Google account password, please click here.
You registered with F1000 via Facebook, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Facebook account password, please click here.
If your email address is registered with us, we will email you instructions to reset your password.
If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance.
Comments on this article Comments (0)